Details of Drug-Drug Interaction
| Drug General Information (ID: DDIRQO451C) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Apixaban | Drug Info | Antithrombin Alfa | Drug Info | |||||
| Drug Type | Small molecule | Protein/peptide | |||||||
| Therapeutic Class | Anticoagulants/Factor Xa Inhibitors | Recombinant Antithrombin | |||||||
| Mechanism of Apixaban-Antithrombin Alfa Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Apixaban | Antithrombin Alfa | |||||||
| Mechanism |
Risk of bleeding Anticoagulant |
Risk of bleeding Anticoagulant |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is recommended if apixaban must be used with other agents that alter hemostasis. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. | ||||||||